Hoth Therapeutics shareholders re-elect all five directors, approve auditor and equity plan at 2023 annual meeting

All of the five nominees for director were elected to serve until the next annual meeting of shareholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the five directors were as follows: Directors For Against Abstentions Broker Non-Votes Robb Knie 220,147 58,177 52,262 993,489 David Sarnoff 217,637 57,613 55,336 993,489 Graig Springer 199,778 78,545 52,263 993,489 Wayne Linsley 207,197 70,970 52,419 993,489 Jeff Pavell 213,588 63,044 53,954 993,489

The shareholders approved the ratification of the appointment of Withum as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The result of the votes to approve Withum was as follows: For Against Abstain 1,111,058 158,230 54,787

The shareholders approved the Amended and Restated 2022 Plan. The result of the votes to approve the Amended and Restated 2022 Plan was as follows: For Against Abstain Broker Non-Votes 190,903 112,224 27,459 993,489